Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Cervical Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
39 drugs · 148 active trials
4 drugs · 53 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | Sep 8, 2009 |
| Veliparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | Oct 28, 2009 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2001-12 |
| Celecoxib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2001-08 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-11 |
| Rucaparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jun 29, 2018 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 14, 2012 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-03 |
| Erlotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-04 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-10 |
| Imiquimod | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 1999-06 |
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-10 |
| Panitumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-02 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 1996-02 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-03 |
| Anastrozole | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 28, 2021 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2000-04 |
| Aspirin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 1, 2017 |
| Belinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-12 |
| Carboplatin/Paclitaxel Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-08 |
| Cemiplimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 28, 2021 |
| Cobimetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 7, 2017 |
| Denosumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 13, 2017 |
| Enzalutamide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 24, 2016 |
| Eribulin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 9, 2012 |
| Etoposide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1993-06 |
| Exemestane | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 15, 2017 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-11 |
| Nedaplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-11 |
| Niraparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 29, 2017 |
| Rigosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-03 |
| Selinexor | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 9, 2014 |
| Sorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-06 |
| Taxol | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 18, 2021 |
| Thalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-09 |
| Uprosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-10 |
| Valproic Acid | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 7, 2018 |
| Dordaviprone | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 23, 2023 |
| Elimusertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 25, 2021 |
| Hyperthermic Intraperitoneal Chemotherapy | Phase 1 | Early Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 13, 2022 |
| Talazoparib | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 26, 2019 |
| Abemaciclib | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 12, 2019 |
| Abexinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 31, 2021 |
| Alisertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-08 |
| Brentuximab Vedotin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 29, 2020 |
| Buparlisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 29, 2014 |
| Futibatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 24, 2023 |
| Infigratinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-01 |
| Margetuximab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 18, 2017 |
| Porcupine Inhibitor WNT974 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2011 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.